On March 17, 2026 Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a biotechnology company pioneering the field of degrader antibody conjugates (DACs), reported that new preclinical data on ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload for the treatment of acute myeloid leukemia (AML), will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22 in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Orum’s two posters on ORM-1153 will highlight preclinical efficacy, pharmacology, and non-human primate safety findings that support advancement toward clinical development in AML.
"The data being presented at AACR (Free AACR Whitepaper) reflect continued progress for ORM-1153 and Orum’s Dual-Precision TPD² approach," said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. "These preclinical data, including repeat-dose non-human primate studies, support advancement toward clinical development and underscore the potential of our approach to expand the therapeutic window beyond conventional cytotoxic antibody-drug conjugates."
Orum’s AACR (Free AACR Whitepaper) 2026 Presentation Details
Both posters will be presented on Monday, April 20, from 9 am to 12 pm PDT.
ORM-1153: A Novel CD123-Targeting Degrader Antibody Conjugate with Proprietary GSPT1 Degrading Payload for the Treatment of Acute Myeloid Leukemia
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Drug Conjugates and Linker Engineering 2
Location: Poster Section 13
Poster Board Number: 7
Poster Number: 1710
ORM-1153: A Next-Generation CD123-Targeting Degrader Antibody Conjugate (DAC)
Session Category: Experimental and Molecular Therapeutics
Session Title: Quantitative Pharmacology and Translational Modeling
Location: Poster Section 17
Poster Board Number: 12
Poster Number: 1824
Posters will be available on Orum’s website following the presentation.
About ORM-1153
ORM-1153 is a CD123-targeting degrader antibody conjugate developed using Orum’s Dual-Precision TPD² approach. The molecule conjugates a proprietary GSPT1-degrading payload to an anti-CD123 antibody with high internalization efficiency via a β-glucuronide cleavable linker. By combining tumor-selective antibody delivery with targeted protein degradation, ORM-1153 is designed to induce cancer cell death through degradation of GSPT1, a protein implicated in cell survival, including in TP53-mutant AML, while minimizing effects on normal tissues.
About Orum’s TPD² Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
(Press release, Orum Therapeutics, MAR 17, 2026, View Source [SID1234663646])